- FibroBiologics Announces 2024 Annual Meeting of Stockholders
- FibroBiologics Files 2024 First Quarter Report
- FibroBiologics to Present at the BIO International Convention 2024
- FibroBiologics Plans to Collaborate with Charles River to Manufacture Fibroblast-based Spheroids
- FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
- FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
- FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
More ▼
Key statistics
On Thursday, Fibrobiologics Inc (SG0:FRA) closed at 10.70, -12.92% below its 52-week high of 12.29, set on Feb 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.70 |
---|---|
High | 10.70 |
Low | 10.70 |
Bid | -- |
Offer | -- |
Previous close | 10.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 32.72m |
Free float | 22.79m |
P/E (TTM) | -- |
Market cap | 371.36m USD |
EPS (TTM) | -0.9149 USD |
Data delayed at least 15 minutes, as of May 16 2024.
More ▼